Market capitalization | $230.39m |
Enterprise Value | $-151.97m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.91 |
EV/Sales (TTM) EV/Sales | -3.75 |
P/S ratio (TTM) P/S ratio | 5.68 |
P/B ratio (TTM) P/B ratio | 0.60 |
Revenue (TTM) Revenue | $40.56m |
EBIT (operating result TTM) EBIT | $-220.55m |
As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.
11 Analysts have issued a Zentalis Pharmaceuticals Inc forecast:
11 Analysts have issued a Zentalis Pharmaceuticals Inc forecast:
Jun '24 |
+/-
%
|
||
Net Profit | -195 -195 |
32%
32%
|
|
Depreciation and Amortization | 1.34 1.34 |
7%
7%
|
|
Stock Compensation | 53 53 |
13%
13%
|
|
Operating Cash Flow | -166 -166 |
16%
16%
|
|
Investments | 0.49 0.49 |
77%
77%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | -167 -167 |
17%
17%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Zentalis Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers in the United States. Its lead product candidate is the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase I/II clinical trial for the treatment of breast cancer. The company is also developing ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2 for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor that is in Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer. Zentalis Pharmaceuticals, LLC was founded in 2014 and is based in New York, New York.
Head office | United States |
CEO | Kimberly Blackwell |
Employees | 168 |
Founded | 2014 |
Website | www.zentalis.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.